Brought to you by 
Targacept reverse merges with Catalyst Biosciences
10 Sep 2020
Executive Summary
Publicly traded Targacept Inc. reverse merged with fellow biotech, privately held Catalyst Biosciences Inc. The combined entity will retain Catalyst's name, will be owned 65% by Catalyst's investors (subject to adjustment), and is expected to have $40mm in cash at closing ($35mm from Targacept and the rest from Catalyst). The new board will have four Catalyst and three Targacept directors.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Targacept reverse merges with Catalyst Biosciences
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice